This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

US Prescription Medical Food Company Appoints Board Of International Advisors

SCOTTSDALE, Ariz., April 10, 2013 /PRNewswire/ -- Prismic Pharmaceuticals, Inc., a Scottsdale, Arizona-based, emerging pharmaceutical company specializing in prescription Medical Foods, today announced the appointment of a number of International Advisors to its International Commercial Advisory Board.  Board members will act as a "sounding board" for Prismic's senior management and Board of Directors in terms of providing input and opinions regarding pharmaceutical/healthcare industry developments, latest trends and practices on a local and international basis.  Recently appointed advisors include: 

  • Antoni Esteve, Ph.D., ( Spain) who is a member of the Board of Directors of Laboratorios del Dr. Esteve, S.A., one of Spain's largest pharmaceutical and chemical manufacturing companies with operations in 40 countries and a presence in more than 60.  
  • Cosimo Pulli , Ph.D., ( Italy) who serves as the senior executive responsible for Emerging Markets at Chiesi Farmaceutici Spa, one Italy's major pharmaceutical companies and the leader in R&D investment.  
  • Massimo Bonsi, ( Eastern Europe) who is the Founder and CEO of the Solartium Group based in Bucharest, Romania, and who has significant pharmaceutical industry knowledge and expertise in the Eastern European region.
  • Anthony H. Wild , Ph.D., (International) the former President of Warner-Lambert's Parke-Davis global Pharmaceutical business.  Currently, Dr. Wild is a member of the Board of Directors of Ranbaxy Laboratories and several privately-owned specialty pharmaceutical companies. He also is on the board of advisors of Auven Therapeutics, a pharmaceutical venture fund. 

Additionally, Prismic has appointed  Marco Cartolari, the founder and, until its recent acquisition, CEO of Scharper SpA, as a Special Advisor to the Board of Directors. Under Cartolari's leadership, Scharper pioneered the development of nutraceuticals and highly scientific "medical food" type products in Italy, and promoted/detailed those products to physicians via Scharper's own sales force

Commenting on these appointments, Peter Moriarty, the Chairman and CEO of Prismic Pharmaceuticals stated, "Prismic is honored to have such a distinguished group of International Advisors.  Their pharmaceutical industry knowledge and perspectives will be of great value to our senior management team and our Board of Directors."

About Prismic Pharmaceuticals, Inc. Prismic Pharmaceuticals, Inc., is a privately held pharmaceutical company focused on the development and marketing of prescription medical foods for the clinical dietary management of the metabolic processes associated with many of the disorders associated with the aging population, particularly where inflammation is involved.  The company is based in Scottsdale, Arizona, and was founded in 2011. Contact 480.422.1810 or visit www.PrismicPharma.com .

INFORMATION CONTACT: Peter MoriartyTel: 480.422.1810

SOURCE Prismic Pharmaceuticals, Inc.

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,915.07 -70.54 -0.42%
S&P 500 1,964.68 -8.15 -0.41%
NASDAQ 4,396.2040 -22.83 -0.52%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs